{"schema_version":"secwatch.filing_event.v1","accession":"0001787306-23-000022","form_type":"8-K","ticker":"ARQT","cik":"0001787306","company_name":"Arcutis Biotherapeutics, Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.545909+00:00","generated_at":"2026-06-18T22:29:13.341218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcutis Q4 2022 net loss $72M; ZORYVE revenue $3M in first full quarter","bullets":["Net product revenue for ZORYVE was $3.0M in Q4 2022, first full quarter since August 2022 launch.","Net loss of $72.0M ($1.18/share) in Q4 2022 vs $71.3M ($1.42/share) in Q4 2021.","Full-year 2022 net loss $311.5M ($5.66/share) vs $206.4M ($4.18/share) in 2021.","Cash, equivalents, and marketable securities $410.8M as of Dec 31, 2022.","Positive Phase 3 atopic dermatitis results; NDA submitted for roflumilast foam in seborrheic dermatitis."],"urls":{"canonical":"https://secwatch.observer/filing/0001787306-23-000022","json":"https://secwatch.observer/filing/0001787306-23-000022.json","markdown":"https://secwatch.observer/filing/0001787306-23-000022.md","text":"https://secwatch.observer/filing/0001787306-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/0001787306-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/arqt-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:29:13.341218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f2a9953b887acedab89787100de00cc710a1654","claim":"Arcutis Biotherapeutics, Inc. reported the year ended December 31, 2022 results: revenue $3.7 million.","evidence_excerpt":"Net product revenues for the year ended December 31, 2022 were $3.7 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/0001787306-23-000022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$3.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5cb64b74895656fce2e86084b50c29b259703702","claim":"Arcutis Biotherapeutics, Inc. reported the quarter ended December 31, 2022 results: revenue $3.0 million.","evidence_excerpt":"Net product revenues for the quarter ended December 31, 2022 related to sales of ZORYVE were $3.0 million driven by unit demand.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/0001787306-23-000022-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$3.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}